Bruker Announces Quarterly Dividend
14 Agosto 2023 - 8:00AM
Business Wire
Bruker Corporation (Nasdaq: BRKR) today announced that its Board
of Directors has approved payment of a quarterly cash dividend in
the amount of $0.05 per share on the Company’s common stock. The
dividend will be paid on September 15, 2023 to stockholders of
record as of September 1, 2023.
About Bruker Corporation
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high performance scientific instruments and high
value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial research, semiconductor metrology and cleantech
applications. Bruker offers differentiated, high-value life science
and diagnostics systems and solutions in preclinical imaging,
clinical phenomics research, proteomics and multiomics, spatial and
single-cell biology, functional structural and condensate biology,
as well as in clinical microbiology and molecular diagnostics. For
more information, please visit: www.bruker.com.
Forward-Looking Statements
Any statements contained in this press release which do not
describe historical facts may constitute forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, including, but not limited to, statements regarding
expected quarterly cash dividends in 2023. Any forward-looking
statements contained herein are based on current expectations, but
are subject to risks and uncertainties that could cause actual
results to differ materially from those indicated, including, but
not limited to, risks and uncertainties relating to COVID-19, the
length and severity of any recession and the impact on global
economic conditions, the impact of supply chain challenges,
including inflationary pressures, the impact of geopolitical
tensions and any sanctions, including any reduction in natural gas
exports from Russia resulting from its ongoing conflict with
Ukraine and resulting market disruptions, such as higher prices for
and reduced availability of key metals used in our products,
continued volatility in the capital markets, the impact of
increased interest rates, the integration and assumption of
liabilities of businesses we have acquired or may acquire in the
future, our restructuring and cost-control initiatives, changing
technologies, product development and market acceptance of our
products, the cost and pricing of our products, manufacturing and
outsourcing, competition, dependence on collaborative partners, key
suppliers and third party distributors, capital spending and
government funding policies, changes in governmental regulations,
intellectual property rights, litigation, exposure to foreign
currency fluctuations, the impact of foreign currency exchange
rates, our ability to service our debt obligations and fund our
anticipated cash needs, the effect of a concentrated ownership of
our common stock, loss of key personnel, payment of future
dividends and other risk factors discussed from time to time in our
filings with the Securities and Exchange Commission, or SEC. These
and other factors are identified and described in more detail in
our filings with the SEC, including, without limitation, our annual
report on Form 10-K for the year ended December 31, 2022, as may be
updated by our quarterly reports on Form 10-Q. We expressly
disclaim any intent or obligation to update these forward-looking
statements other than as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230814281465/en/
Justin Ward Sr. Director, Investor Relations & Corporate
Development Bruker Corporation T: +1 (978) 313-5800 E:
Investor.Relations@bruker.com
Bruker (NASDAQ:BRKR)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Bruker (NASDAQ:BRKR)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024